Presenters
Director, University of Saarland
MICHAL BÖHM, MD
Course Details
The lecture is about discussion on the results of the EMPagliflozin outcomE tRial in patients With chrOnic heaRt failure with Reduced ejection fraction and Preserved ejection fraction.
CPD Points: 0.75 Point
PRC Program No: PROG-2021-15893
Empagliflozin Heart Failure: EMPEROR-Reduced and Preserved Studies Course Outline
- To provide updates on the new indication of Empagliflozin in the treatment of patients with Heart failure reduced ejection fraction with or without T2D.
- Discussion on the Unmet Needs in Heart Failure Treatment touching on the current available therapies in HF.
- To discuss on early evidence of heart failure benefit in SGLT-2i.
- To discuss on the trial results of EMPagliflozin outcomE tRial in patients With chrOnic heaRt failure with Preserved ejection fraction (EMPEROR-Preserved).
- To discuss on the trial results of EMPagliflozin outcomE tRial in patients With chrOnic heaRt failure with Reduced ejection fraction (EMPEROR-Reduced).